CONSENT VALIDITY IN DYNAMIC IMMUNE THERAPIES

1. INTRODUCTION

Dynamic immune therapies involve medical interventions that modify, stimulate, suppress or regulate the functioning of the human immune system. They may include immunotherapy, immune checkpoint inhibitors, therapeutic vaccines, cellular immunotherapies, gene-modified immune-cell treatments and other evolving immune-based interventions.

These treatments may produce changing biological responses, delayed adverse effects, unexpected immune reactions and long-term consequences. Therefore, consent obtained before treatment must address not only the initial intervention but also foreseeable changes in treatment, monitoring requirements and newly identified risks.

Consent validity in dynamic immune therapies requires informed decision-making, voluntariness, decision-making capacity, adequate disclosure and continuing communication between healthcare professionals and patients. In India, these principles are primarily governed by Article 21 of the Constitution, medical negligence law, professional ethics and patient-rights protections.

2. LEGAL FRAMEWORK GOVERNING CONSENT

A. CONSTITUTIONAL FRAMEWORK

Article 21 of the Constitution protects life, personal liberty, bodily integrity and individual autonomy. Medical interventions affecting immune functioning must respect the patient's right to make informed decisions concerning their body.

Article 14 also supports equal and non-arbitrary treatment within healthcare institutions.

B. MEDICAL PROFESSIONAL ETHICS

The National Medical Commission's professional conduct requirements establish duties concerning patient information, consent, confidentiality and professional responsibility.

C. CONSUMER PROTECTION ACT, 2019

Patients may seek remedies for deficient medical services, including negligence involving inadequate disclosure, improper administration or failure to monitor treatment.

D. TORT AND MEDICAL NEGLIGENCE LAW

A medical practitioner may incur liability where treatment is performed without valid consent, material risks are negligently concealed or treatment exceeds the authority granted by the patient.

3. ESSENTIAL REQUIREMENTS OF VALID CONSENT

A. INFORMED CONSENT

Before commencing dynamic immune therapy, the patient should receive information concerning:

Nature and purpose of the immune intervention.

Expected therapeutic benefits and limitations.

Material and reasonably foreseeable adverse effects.

Potential autoimmune reactions and immune-system complications.

Available alternative treatments.

Consequences of refusing or discontinuing treatment.

Long-term monitoring and follow-up obligations.

B. VOLUNTARY CONSENT

Consent must be given freely without coercion, intimidation, misleading representations or improper pressure arising from the patient's medical condition.

C. CAPACITY TO CONSENT

The patient must possess the ability to understand relevant information, appreciate its consequences and communicate a decision. Where capacity is absent, legally appropriate substitute decision-making procedures must be followed.

D. SPECIFIC CONSENT

Consent for one immune therapy cannot automatically authorise a substantially different treatment, additional invasive procedure or unrelated experimental intervention.

E. DOCUMENTATION

Consent documentation should identify the treatment, disclosed risks, alternatives, patient's questions, decision-making capacity and any limitations imposed by the patient.

4. SPECIAL REQUIREMENTS FOR DYNAMIC IMMUNE THERAPIES

A. CONTINUING CONSENT

Consent should be treated as an ongoing process rather than a single signature. Patients must receive updated information when clinically significant developments materially change the treatment's risks or benefits.

B. NEWLY IDENTIFIED RISKS

If previously undisclosed material complications emerge, healthcare professionals should communicate relevant information and reconsider whether continued treatment remains consistent with the patient's informed decision.

C. TREATMENT MODIFICATIONS

A substantial change in the therapeutic intervention, treatment purpose or risk profile may require renewed consent.

D. EXPERIMENTAL IMMUNE THERAPIES

Research-based interventions require additional safeguards, including independent ethics review, research-specific informed consent and appropriate protections against therapeutic misconception.

E. WITHDRAWAL OF CONSENT

Patients generally retain the right to withdraw consent. However, doctors should explain foreseeable consequences and arrange clinically appropriate discontinuation or alternative care. Withdrawal from research participation must also be distinguished from obligations concerning already collected research data and safety follow-up.

5. IMPORTANT JUDICIAL DECISIONS

1. Samira Kohli v. Dr. Prabha Manchanda (2008)

<case>Supreme Court of India</case>

Direct authority. The Supreme Court established that consent must be real, voluntary and related to the specific treatment or procedure undertaken. Consent for one procedure does not automatically authorise another substantially different procedure.

Relevance: Applicable to additional or materially modified immune interventions undertaken without appropriate consent.

2. K.S. Puttaswamy v. Union of India (2017)

Analogous authority. The Supreme Court recognised privacy and individual autonomy as fundamental rights under Article 21.

Relevance: Supports bodily autonomy and informed medical decision-making.

3. Common Cause v. Union of India (2018)

Analogous authority. The Supreme Court recognised patient autonomy and the right to refuse medical treatment in the context of end-of-life decisions.

Relevance: Supports the principle that competent patients retain control over treatment decisions.

4. Suchita Srivastava v. Chandigarh Administration (2009)

Analogous authority. The Supreme Court recognised bodily integrity and reproductive autonomy.

Relevance: Supports the broader principle that medical interventions require respect for individual bodily autonomy.

5. Jacob Mathew v. State of Punjab (2005)

Analogous authority. The Supreme Court explained the legal principles governing professional medical negligence.

Relevance: Doctors administering dynamic immune therapies must exercise reasonable professional competence and care.

6. V. Kishan Rao v. Nikhil Super Speciality Hospital (2010)

Analogous authority. The Supreme Court discussed medical negligence and consumer remedies.

Relevance: Supports accountability where deficient treatment administration, disclosure or monitoring causes actionable harm.

6. PRACTICAL COMPLIANCE OBLIGATIONS

Healthcare institutions should:

Develop therapy-specific informed consent forms.

Explain foreseeable immune-related complications.

Establish procedures for communicating newly identified material risks.

Obtain renewed consent for substantial treatment modifications.

Maintain records of patient decisions and treatment discussions.

Provide appropriate adverse-event monitoring.

Protect patient confidentiality and research information.

Respect treatment refusal and withdrawal of consent.

Obtain additional research consent where applicable.

Ensure that vulnerable patients receive appropriate decision-making safeguards.

7. LEGAL CONSEQUENCES OF INVALID CONSENT

Invalid consent may expose healthcare professionals and institutions to civil liability, consumer proceedings and professional disciplinary action. Criminal liability may arise where its specific statutory requirements are established.

A signed consent document is not conclusive proof of informed consent. Courts may examine the actual information disclosed, the patient's understanding, the nature of the intervention and whether the procedure remained within the authorised scope.

8. CONCLUSION

Consent validity in dynamic immune therapies requires a continuing, transparent and patient-centred process. The changing nature of immune interventions makes updated disclosure, procedure-specific authorisation and respect for withdrawal particularly important. Indian judicial principles, especially those established in Samira Kohli, Puttaswamy and Common Cause, provide a foundation for protecting bodily autonomy and medical decision-making. Healthcare institutions must combine meaningful consent procedures with appropriate clinical monitoring, accurate documentation and continuing patient communication.